The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

The Food and Drug Administration (FDA) has accepted for review a resubmission of the Biologics License Application (BLA) for bevacizumab-vikg (ONS-5010) for the treatment of wet age-related macular ...

Artificial intelligence (AI) recommendations are more often rated as better quality than final recommendations of physicians for virtual care visits made by patients with respiratory, urinary, vaginal ...

Physicians should counsel patients considering whether to start treatment for chronic noncancer pain about benefits and harms of cannabis or cannabinoids.

Seventy-eight percent of unvaccinated adults are unsure if they were eligible for vaccination or thought they were not.

Compounded versions, made during shortages, have cost less than $200, but regulators plan to stop allowing those soon.

The rising trajectory in the inability to pay for health care is a disturbing trend that is likely to continue and even accelerate,” said Tim Lash.

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Application (sBLA) for fremanezumab-vfrm to include the ...

Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset.

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.

Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection by a health care professional.